Skip to main content

Table 2 Univariate analysis of clinical factors and GPS for overall survival (n = 402)

From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

 

Patients (%)

mOS months (95% CI)

P-value

Age

<60

203 (50.5)

11.6 (10.1-13.2)

0.808

≥ 60

199 (49.5)

12.0 (9.9-14.1)

 

Gender

Male

293 (72.9)

11.7 (10.1-13.3)

0.952

Female

109 (27.1)

12.1 (10.6-13.6)

 

Liver Mets

Yes

125 (31.1)

11.4 (8.5-14.3)

0.352

No

277 (68.9)

12.0 (10.7-13.3)

 

Peritoneal Mets

Yes

159 (39.6)

9.9 (8.4-11.5)

0.023

No

243 (60.4)

13.0 (11.2-14.8)

 

Bone Mets

Yes

28 (7.0)

8.2 (7.1-9.3)

0.117

No

374 (93.0)

12.1 (10.9-13.2)

 

Albumin

<3.5

77 (19.2)

7.7 (5.9-9.5)

0.001

≥ 3.5

325 (80.8)

12.4 (10.7-14.2)

 

CRP

≤ 1

262 (64.9)

14.8 (12.7-17.0)

0.001

>1

140 (34.8)

8.7 (7.3-10.2)

 

ECOG PS

0-1

329 (81.8)

12.4 (10.9-13.8)

0.003

≥ 2

73 (48.2)

8.7 (7.3-10.0)

 

GPS

0

238 (59.2)

15.3 (13.1-17.5)

0.001

1

111 (27.6)

8.9 (7.2-10.7)

 

2

53 (13.2)

7.6 (4.9-10.2)

 
  1. mOS: median overall survival, Mets: metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score